Antibacterial peptide potently active against Gram-positive bacteria (PubMed:29174563). May act by selectively inhibiting peptidoglycan biosynthesis through complex formation with the cell wall precursor lipid II (1:1 molar ratio) thus inhibiting cell wall synthesis (By similarity). Shows remarkably activity against resistant isolates such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) at the concentration of micromolar level (PubMed:29174563). Does not act by destroying the membrane integrity, which is consistent with its nonamphiphilic architecture (PubMed:29174563). Acts more rapidly than vancomycin (PubMed:29174563). Shows low hemolysis and cytotoxicity and high serum stability (PubMed:29174563). In vivo, is as efficient as vancomycin to protect mouse peritonitis models from MRSA infections (PubMed:29174563). Has the structural arrangement of an alpha-helix connected to a beta-sheet by disulfide bonds (CSalpha/beta). Belongs to the invertebrate defensin family.